The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

被引：0
|
作者：
Nazha, Aziz [1 ]
Komrokji, Rami S. [2 ]
Garcia-Manero, Guillermo [3 ]
Barnard, John [1 ]
Zimmerman, Cassie [1 ]
Najla, Al Ali [4 ]
Roboz, Gail J. [5 ]
Steensma, David P. [6 ]
DeZern, Amy E. [7 ]
Jabbour, Elias [3 ]
Lee, Sangmin [8 ]
Greenberg, Molly D. [9 ]
List, Alan F. [4 ]
Kantarjian, Hagop M. [3 ]
Maciejewski, Jaroslaw P. [1 ]
Sekeres, Mikkael A. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Weill Cornell New York Presbyterian Hosp, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A PROGNOSTIC MODEL FOR PREDICTING SURVIVAL AFTER STOPPING HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME
    Kim, H.
    Ahn, J. S.
    Do, Y. R.
    Shin, H. J.
    Lee, W. S.
    Joo, Y. D.
    Moon, J. H.
    Lee, H. S.
    Cho, Y. Y.
    LEUKEMIA RESEARCH, 2015, 39 : S28 - S29
  • [32] Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)
    Al-Issa, Karam
    Madanat, Yazan F.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Abuhadra, Nour
    Makhoul, Ahed
    Awada, Hassan
    Asad, Mohammad Fahad B.
    Goyal, Abhinav
    Advani, Anjali S.
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [33] Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment
    Garcia-Manero, Guillermo
    Tallman, Martin S.
    Martinelli, Giovanni
    Ribrag, Vincent
    Yang, Hui
    Balakumaran, Arun
    Chlosta, Sabine
    Zhang, Yayan
    Smith, B. Douglas
    BLOOD, 2016, 128 (22)
  • [34] Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium
    Jabbour, Elias
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Gail, Roboz J.
    Daver, Naval G.
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney D.
    Wang, Xuemei
    Nogueras-Gonzalez, Graciela
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [35] Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
    Komrokji, Rami S.
    Kulasekararaj, Austin G.
    Al Ali, Najla H.
    Kordasti, Shahram Y.
    Bart-smith, Emily
    Benjamin, Craig
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan
    Mufti, Ghulam J.
    Epling-Burnette, Pearlie K.
    BLOOD, 2013, 122 (21)
  • [36] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [37] Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial
    Zeidan, Amer M.
    Zeidner, Joshua F.
    Duffield, Amy
    Knaus, Hanna A.
    Ferguson, Anna
    Sheldon, Katherine
    DeZern, Amy E.
    Gojo, Ivana
    Gore, Steven D.
    Streicher, Howard
    Luznik, Leo
    Smith, B. Douglas
    BLOOD, 2015, 126 (23)
  • [38] Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Qiao, Wei
    Strati, Paolo
    Khan, Navira F.
    Cortes, Jorge E.
    Hoehn, Daniela
    Hu, Jianhua
    Obrien, Susan
    Bryan, Jeffrey
    Prescott, Hillary
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [39] A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure
    Swaminathan, Mahesh
    Borthakur, Gautam
    Kadia, Tapan M.
    Ferrajoli, Alessandra
    Alvarado, Yesid
    Pemmaraju, Naveen
    Bodden, Kristy
    Yearby, Brittany
    Konopleva, Marina
    Khoury, Joseph
    Bueso-Ramos, Carlos
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2207 - 2213
  • [40] A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
    Zeidan, Amer M.
    Knaus, Hanna A.
    Robinson, Tara M.
    Towlerton, Andrea M. H.
    Warren, Edus H.
    Zeidner, Joshua F.
    Blackford, Amanda L.
    Duffield, Amy S.
    Rizzieri, David
    Frattini, Mark G.
    Levy, Yair M.
    Schroeder, Mark A.
    Ferguson, Anna
    Sheldon, Katherine E.
    DeZern, Amy E.
    Gojo, Ivana
    Gore, Steven D.
    Streicher, Howard
    Luznik, Leo
    Smith, B. Douglas
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3519 - 3527
12345